Will newer tyrosine kinase inhibitors have an impact in AML?

Research output: Contribution to journalReview articlepeer-review

Abstract

FLT3 inhibition has been a goal of acute myeloid leukemia (AML) therapy since FLT3 mutations were discovered to have a role in AML. Several FLT3 inhibitors have been developed in the last several years, beginning with less potent, less selective agents. The newer FLT3 inhibitors appear to be more potent in vivo and have shown more promise than the older agents in monotherapy trials.

Original languageEnglish (US)
Pages (from-to)489-494
Number of pages6
JournalBest Practice and Research: Clinical Haematology
Volume23
Issue number4
DOIs
StatePublished - Dec 2010

Keywords

  • AC220
  • AML
  • Acute myeloid leukemia
  • FLT3
  • Inhibitor
  • KW-2449
  • Lestaurtinib
  • Midostaurin
  • Sorafenib

ASJC Scopus subject areas

  • Oncology
  • Clinical Biochemistry

Fingerprint

Dive into the research topics of 'Will newer tyrosine kinase inhibitors have an impact in AML?'. Together they form a unique fingerprint.

Cite this